Table 2.

Summary of sample counts, quintile groupings used for multi-omic BMD modeling, and number of molecules meeting statistical criteria^a.

		All Molecular Endpoints	CpG site DNA Methylation	miRNA Expression	mRNA Expression	Protein Expression	Multi-omic Profiles through WGCNA
Number of Cord Blood Samples Evaluated		59	48	40	38	50	31
Number of Molecules Evaluated for Significant Association to U-tAs		‐	424,935	1,347	25,412	507	‐
Number of Molecules Significantly Associated with U-tAs and analyzed through BMD modeling		‐	3,493b	12c	315d	111e	5 MEs
Median U-tAs (ug/L) used for BMD modeling [number of subjects]
	Quintile #1	8.5 [12]	8.5 [10]	8.4 [11]	8.4 [9]	8.5 [10]	8.4 [7]
	Quintile #2	15.3 [12]	15.3 [10]	15 [8]	15 [8]	15.1 [9]	15 [6]
	Quintile #3	28.1 [11]	29.4 [8]	32.6 [5]	32.6 [5]	28.1 [9]	32.6 [3]
	Quintile #4	40.2 [12]	40.2 [8]	82.1 [5]	82.1 [5]	41.2 [11]	82.1 [5]
	Quintile #5	161.4 [12]	161.4 [12]	157.8 [11]	157.8 [11]	164.9 [11]	161.4 [10]
Number of Molecules Significantly Associated with U-tAs and Showing Dose-Dependent Changes through BMD Modeling		‐	1,629	12	96	14	4 MEs

^aStatistical criteria were adapted for each analysis to suite the differing platforms and value distributions, thus making the number of genes/proteins identified as significantly associated with U-tAs not directly comparable across molecular endpoints

^bCpG sites were previously identified by Rojas et al. (2015), and filtered here to include those annotated to known genes

^cmiRNAs were previously identified by Rager et al. (2014)

^dmRNAs were previously identified by Rager et al. (2014), and filtered here to includemRNAs annotated to known genes. These 315 mRNAs were represented by 364 probeset IDs.

^eProteins were previously identified by Bailey et al. (2014). These 111 proteins were represented by 114 array probes.